Iván R. González: Denosumab vs. Zoledronic Acid in metastatic bone disease
Iván R. González, Medical Oncologist at the Comprehensive Cancer Center, Hospital Ángeles Puebla, shared on X:
“An interesting meta-analysis evaluates Denosumab vs. Zoledronic Acid in metastatic bone disease (MBD):An analysis of 7,441 patients compared both treatments, highlighting their therapeutic profiles:
Denosumab (Dmab):
Greater efficacy in reducing skeletal-related events (SREs), such as bone radiotherapy and pathological fractures (39% fewer in breast cancer).
Prolongs SRE-free intervals in most cancers.
Favorable safety profile: less renal toxicity and acute-phase reactions.
Delays pain progression and improves quality of life.
Considerations:Higher cost.
Risk of hypocalcemia and jaw osteonecrosis.
Zoledronic Acid (ZA):
A more cost-effective alternative in many contexts with comparable benefits in overall survival and disease progression.
While Dmab offers clinical advantages, the cost-effectiveness of both agents varies depending on cancer type and healthcare systems. Further research is essential to explore pain management, quality of life, and economic value to optimize MBD treatment. ”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023